Imipenem
This carbapenem antibiotic is used to treat serious and resistant bacterial infections by inhibiting bacterial cell wall synthesis. It is always administered in combination with cilastatin, which prevents its breakdown in the kidneys and reduces kidney toxicity. It is effective against a broad range of gram-positive, gram-negative, and anaerobic bacteria.
Molecular Weight
299.3500 g/mol
LogP
-0.70
TPSA
142.00 Ų
Lipinski RO5
Pass
Therapeutic Areas
Mechanism of Action
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.
2D Structure
Cite this structure
Embed this structure
SMILES
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(SCCNC=N)C[C@H]12.O
InChI
InChI=1S/C12H17N3O4S.H2O/c1-6(16)9-7-4-8(20-3-2-14-5-13)10(12(18)19)15(7)11(9)17;/h5-7,9,16H,2-4H2,1H3,(H2,13,14)(H,18,19);1H2/t6-,7-,9-;/m1./s1
Molecular Formula
C12H17N3O4S
HBD / HBA
3 / 6
Rotatable Bonds
6
Heavy Atoms
20
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Frequently Asked Questions
This carbapenem antibiotic is used to treat serious and resistant bacterial infections by inhibiting bacterial cell wall synthesis. It is always administered in combination with cilastatin, which prevents its breakdown in the kidneys and reduces kidney toxicity. It is effective against a broad range of gram-positive, gram-negative, and anaerobic bacteria.
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.
Yes, Imipenem is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL43708. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 104838. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="imipenem"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/imipenem/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/imipenem/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/imipenem/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="imipenem"></drugfyi-drug>